# Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects

> **NCT06444191** · PHASE1 · COMPLETED · sponsor: **Principia Biopharma, a Sanofi Company** · enrollment: 23 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Rilzabrutinib

## Key facts

- **NCT ID:** NCT06444191
- **Lead sponsor:** Principia Biopharma, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-04
- **Primary completion:** 2021-04-12
- **Final completion:** 2021-04-12
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2024-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06444191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06444191, "Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06444191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*